Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00003397
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT00077194
What this trial is testing

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 35
Early research (Phase 1)Active Not RecruitingNCT01955499
What this trial is testing

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic Lymphoma+7 more
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Looking for participantsNCT04871607
What this trial is testing

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 33
Early research (Phase 1)Ended earlyNCT00860171
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin Lymphoma+3 more
Fred Hutchinson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT06066203
What this trial is testing

GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Who this might be right for
Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT00004169
What this trial is testing

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Who this might be right for
Lymphoma
Northwestern University
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Study completedNCT02611323
What this trial is testing

Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 133
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Study completedNCT00478959
What this trial is testing

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin Disease
University Health Network, Toronto 30
Early research (Phase 1)Looking for participantsNCT07082803
What this trial is testing

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Who this might be right for
LymphomaLymphoma, Non Hodgkin
Treeline Biosciences, Inc. 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361
What this trial is testing

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more
Luminary Therapeutics 90
Testing effectiveness (Phase 2)Ended earlyNCT03379051
What this trial is testing

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Who this might be right for
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
TG Therapeutics, Inc. 78
Testing effectiveness (Phase 2)Study completedNCT00737529
What this trial is testing

Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Who this might be right for
Mantle Cell Lymphoma
Celgene 134
Early research (Phase 1)Looking for participantsNCT05755087
What this trial is testing

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+6 more
Lapo Alinari
Early research (Phase 1)Active Not RecruitingNCT05879744
What this trial is testing

CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
NHLNHL, Relapsed, Adult
Cullinan Therapeutics Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Next Page
18